Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

The evidence for the efficiency and safety of dapoxetine in treating premature ejaculation

Ахвледиани Н. Д., Матюхов И. П.
Урология
Вып. 5, С. 106-110
Опубликовано: 2017
Тип ресурса: Обзор

DOI:10.18565/urology.2017.5.106-110

Аннотация:
The aim of the study is to assess the evidence on the efficacy and safety of dapoxetine in premature ejaculation (PE). The analysis includes results of randomized placebo-controlled trials, integrative reviews and one meta-analysis on the clinical efficacy and safety of dapoxetine. All studies have shown higher efficacy of dapoxetine in patients with PE compared with placebo. Its administration at a dosage of 30 and 60 mg results in an increase in the coitus duration up to approximately 3 and 3.5 minutes, respectively. The safety profile of dapoxetine allows using it in clinical practice. Dapoxetine is a novel and effective PE drug on the Russian market.
Ключевые слова:
dapoxetine; efficacy; premature ejaculation; primaxetin; safety
benzylamine derivative; dapoxetine; naphthalene derivative; human; male; pathology; pathophysiology; premature ejaculation; Benzylamines; Humans; Male; Naphthalenes; Premature Ejaculation
Язык текста: Русский
ISSN: 1728-2985
Ахвледиани Н. Д. Ника Джумберович 1976-
Матюхов И. П. Игорь Павлович 1984-
Akhvlediani N. D. Nika Dzhumberovich 1976-
Matukhov I. P. Igor` Pavlovich 1984-
The evidence for the efficiency and safety of dapoxetine in treating premature ejaculation
Текст визуальный непосредственный
Урология
Бионика Медиа
Вып. 5 С. 106-110
2017
Обзор
dapoxetine efficacy premature ejaculation primaxetin safety
benzylamine derivative dapoxetine naphthalene derivative human male pathology pathophysiology premature ejaculation Benzylamines Humans Male Naphthalenes Premature Ejaculation
The aim of the study is to assess the evidence on the efficacy and safety of dapoxetine in premature ejaculation (PE). The analysis includes results of randomized placebo-controlled trials, integrative reviews and one meta-analysis on the clinical efficacy and safety of dapoxetine. All studies have shown higher efficacy of dapoxetine in patients with PE compared with placebo. Its administration at a dosage of 30 and 60 mg results in an increase in the coitus duration up to approximately 3 and 3.5 minutes, respectively. The safety profile of dapoxetine allows using it in clinical practice. Dapoxetine is a novel and effective PE drug on the Russian market.